ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats

Shock

Volumn 6, Issue 2, 1996, Pages 112-117

  Albert, Daniel H ^a   Luo, Gongjin ^a   Magoc, Terrance J ^a   Tapang, Paul ^a   Holms, James H ^a   Davidsen, Steven K ^a   Summers, James B ^a   Carter, George W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETOXYMETHYL 3 [7 [[1 (N,N DIMETHYLCARBAMOYL) 6 (4 FLUOROPHENYL) 3 INDOLYL]CARBONYL] 1H,3H PYRROLO[1,2 C]THIAZOL 3 YL]PYRIDINIUM CHLORIDE; ANTITHROMBOCYTIC AGENT; ENDOTOXIN; ENDOTOXIN, ESCHERICHIA COLI; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; PYRIDINIUM DERIVATIVE; TEICHOIC ACID; THIAZOLE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL; ARTICLE; CONSCIOUSNESS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ANTAGONISM; ENDOTOXEMIA; GASTROINTESTINAL HEMORRHAGE; HYPOTENSION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CONSCIOUSNESS; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTOXEMIA; ENDOTOXINS; GASTROINTESTINAL HEMORRHAGE; HYPOTENSION; LIPOPOLYSACCHARIDES; MALE; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PYRIDINIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; TEICHOIC ACIDS; THIAZOLES;

EID: 0030203314     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199608000-00006     Document Type: Article

References (29)

1. Sanchez Crespo M, Fernandez-Gallardo S: Pharmacological modulation of PAF: A therapeutic approach to endotoxin shock. J Lipid Mediators 4:127-144, 1991.
2. Braquet P, Paubert-Braquet M, Bessin P, Vargaftig BB: Platelet-activating factor: A potential mediator of shock. Adv Prostaglandin Thromboxane Leukot Res 7:822-827, 1987.
3. Summers JB, Albert DH: Platelet activating factor antagonists: Adv Pharmacol. Book series. August JT, Anders MW, Murad F, Coyle J (eds). Vol. 32. 1994, San Diego: Academic Press. 67-168.
4. Inarrea P, Gomez-Cambronero J, Pascual J, Ponte MC, Hernando L, Sanchez-Crespo M: Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. Immunopharmacology, 9:45-52, 1985.
5. Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TY: Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats: Studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun 127:799-808, 1985.
6. Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers JB, Carter GW: Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. J Pharm Exper Therap. In press.
7. Davidsen SK, Summers SB, Albert DH, et al: N-(Acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist. J Med Chem 37:4423-4429, 1994.
8. Sahoo SP, Graham DW, Acton J, et al: Synthesis and biological activity of MK 287 (L-680,573): A potent, specific and orally active PAF receptor antagonist. Bioorg Med Chem Lett 1:327-332, 1991.
9. Heuer HO, Keller B, Urich K: Action of the ratemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats. Arch Pharmacol 343:546-550, 1991.
10. Whittaker M, Thompson TM, Spavold ZM, et al: Cyclic ether acetal platelet activating factor (PAF) receptor antagonists. I. 3-pyridyl derivatives. Bioorg Med Chem Lett 3:1493-1498, 1993.
11. Lavé D, James C, Rajoharison H, Bost PE, Cavero I: Pyrrolo[1,2-c]thiazole derivatives: Potent PAF receptor antagonists. Drugs Fut 14:891-898, 1989.
12. Miyazawa S, Okano K, Shimomura N, et al: Structure-activity studies on triazolothienodiazepine derivatives as platelet-activating factor antagonists. Chem Pharm Bull 12:3215-3220, 1991.
13. Yoshikawa T, Furukawa Y, Murakami M, Takemura S, Kondo M: Experimental model of disseminated intravascular coagulation induced by sustained infusion of endotoxin. Res Exp Med 179:223-228, 1981.
14. Imanishi N, Komuro Y, Morooka S: Effect of a selective PAF antagonist SM-10661 ((±)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC). Lipids 26: 1391-1395, 1991.
15. Levi M, ten Cate H, van der Poll T, van Deventer SJ: Pathogenesis of disseminated intravascular coagulation in sepsis. J Am Med Assoc 270: 975-979, 1993.
16. Chang SW, Feddersen CO, Henson PM, Voelkel NF: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79:1498-1509, 1987.
17. Qi M, Jones SB: Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ Shock 32:153-163, 1990.
18. Torley LW, Pickett WC, Carroll ML, et al: Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob Agents Chemother 36:1971-1977, 1992.
19. Wallace JL, Steel G, Whittle BJ, Lagente V, Vargaftig B: Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat: Effects of three platelet-activating factor antagonists. Gastroenterology 93:765-773, 1987.
20. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K: Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther 260:748-755, 1992.
21. Terashita Z, Imura Y, Nishikawa K, Sumida S: Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol, 109:257-261, 1985.
22. Imura Y, Terashita Z, Nishikawa K: Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988. Life Sci 39:111-117, 1986.
23. Kawamura M, Terashita Z, Imura Y, Shino A, Nishikawa K: Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation. Thromb Res 70:281-293, 1993.
24. Tang HM, Teshima DY, Lum B: Effects of the PAF antagonists bepafant and L-659,989 in endotoxic and septic shock. Drug Development Research 29:216-221, 1993.
25. Bussolino F, Arese M, Silvestro L, et al: Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha. Eur J Immunol 24:3131-3139, 1994.
26. Gay JC: Mechanism and regulation of neutrophil priming by platelet-activating factor. J Cell Physiol 156:189-197, 1993.
27. Bhakdi S, Klonisch T, Nuber P, Fischer W: Stimulation of monokine production by lipoteichoic acids. Infect Immun 59:4614-4620, 1991.
28. Williams M, Summers JB: Septic shock: the continuing challenge for an effective therapy. Exp Opin Invest Drugs 3:1051-1056, 1994.
29. Kruse-Elliott KT, Grossman JE, Albert DH, Summers JB, Carter GW, Zimmerman JJ: Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock 5:265-273, 1996.